Hisert Laboratory Search Clinical Trials Find a Researcher Order a Test Our lab performs basic & translational research to understand the role of monocytes and macrophages in modulating airway inflammation in people with cystic fibrosis (CF). Lab Resources & Services The lab is located on National Jewish Health main campus. Current Projects Characterization of macrophage populations in the CF airway, and investigations into how these cells modulate inflammation. How much heterogeneity is present in airway macrophage populations? Does the abundance of populations of macrophage shift during pulmonary exacerbations? How do various medications affect airway macrophages phenotypes? Identification of novel therapeutics / anti-inflammatory medications for people with CF (and other chronic inflammatory airways diseases) Investigations into the role of macrophages in susceptibility of people with CF to NTM infection. View Diagrams Katherine Hisert, MD, PhD + × Katherine Hisert, MD, PhD Katherine Hisert, MD, PhD, is a pulmonologist at National Jewish Health. Dr. Hisert is in the Division of Pulmonary, Critical Care and Sleep Medicine. Assistant Professor Division of Pulmonary, Critical Care & Sleep Medicine Department of Medicine View Full Profile Make an Appointment Personnel Principal Investigator: Katherine “Katie” Hisert, MD, PhD Research Technicians Alma Ochoa Jack Congel Postdoctoral Fellow Jodi Corley, PhD Collaborators Jerry Nick, MD Milene Saavedra, MD Ken Malcolm, PhD William Janssen, MD Eszter Vladar, PhD, Vladar Lab Will DePas, PhD, DePas Lab Publications Nick JA, Malcolm KC, Hisert KB, Wheeler EA, Rysavy NM, Poch K, Caceres S, Lovell VK, Armantrout E, Saavedra MT, Calhoun K, Chatterjee D, Aboellail I, De P, Martiniano SL, Jia F, Davidson RM. Culture independent markers of nontuberculous mycobacterial (NTM) lung infection and disease in the cystic fibrosis airway. Tuberculosis (Edinb). 2023 Jan;138:102276. doi: 10.1016/j.tube.2022.102276. Epub 2022 Nov 17. PubMed PMID: 36417800. Caverly LJ, Riquelme SA, Hisert KB. The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation. Clin Chest Med. 2022 Dec;43(4):647-665. doi: 10.1016/j.ccm.2022.06.007. Review. PubMed PMID: 36344072. Carter SC, Franciosi AN, O'Shea KM, O'Carroll OM, Sharma A, Bell A, Keogan B, O'Reilly P, Coughlan S, Law SM, Gray RD, Hisert KB, Singh PK, Cooke G, Grogan B, De Gascun CF, Gallagher CG, Nicholson TT, Quon BS, McKone EF. Acute Pulmonary Exacerbation Phenotypes in Patients with Cystic Fibrosis. Ann Am Thorac Soc. 2022 Nov;19(11):1818-1826. doi: 10.1513/AnnalsATS.202111-1266OC. PubMed PMID: 35713619; PubMed Central PMCID: PMC9667812. View All Publications